MMB101 is a humanized anti-TIGIT monoclonal antibody designed to target a novel epitope spanning multiple PVR binding sites for optimized functional coverage.
Differentiated epitope coverage to benchmark anti-TIGIT antibodies
Preclinical evidence of anti-tumor activity in multiple cancer models
Functional synergism with PD-1 drugs
Immunomodulation of central memory T cells (Tcm) and effector memory T cells (Tem) for long-term response
